Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

New study reveals conflicting role of two subtypes of pancreatic cancer stroma

Dense surrounding tissue can block drugs from reaching pancreatic cancer tumors, but it can also help prevent the cancer from spreading. Now a new study by UNC Lineberger Comprehensive Cancer Center researchers and collaborators helps explain the conflicting role of the surrounding tissue known as stroma. In the study, the researchers revealed that based on molecular characteristics, there are two subtypes of pancreatic cancer stroma.

9 Sep 2015

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

The University of Pennsylvania's Abramson Cancer Center (ACC) has received an "exceptional" rating by the National Cancer Institute during an extensive peer-review process for its five-year competitive research support grant. The rating is the highest possible for an NCI cancer center.

9 Sep 2015

CenseoHealth partners with Health Insurance Marketplace to provide health assessment solutions

CenseoHealth an industry leader of physician-performed health assessment solutions for Medicare Advantage plans, has partnered with Health Insurance Marketplace (HIX) and Commercial plans in 2015 to provide their members health assessments at their home, workplace, primary care physician's office or retail clinic.

4 Sep 2015

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not, because their risk of cancer recurrence is too high? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment option is best for patients with Klatskin carcinoma, one type of bile duct cancer.

1 Sep 2015

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that its BNC101 IND submission has passed review by the US Food and Drug Administration (FDA).

31 Aug 2015

Moffitt researchers hope to improve pancreatic cancer survival rates by developing blood test to identify IPMNs

Pancreatic cancer is the fourth most common cause of cancer-related death in the United States and has a 5-year survival rate of only 6 percent, which is the lowest rate of all types of cancer according to the American Cancer Society.

29 Aug 2015

Physical inactivity poses important clinical, public health and fiscal challenges for the U.S.

What do a prominent physiologist and two-time survivor of pancreatic cancer and a world-renowned researcher whose landmark discoveries on aspirin, drug therapies of proven benefit and therapeutic lifestyle changes that have saved more than 1.1 million lives have in common? They are both passionate about the importance of regular physical activity in reducing risks of dying from heart attacks and strokes, as well as developing diabetes, hypertension and colon cancer. And more importantly, enhancing mental health and fostering healthy muscles, bones and joints in all Americans from childhood to the elderly.

27 Aug 2015

UH research points to promising target in treatment of pancreatic cancer

Pancreatic cancer is extremely deadly and often has a poor prognosis. Ranked as the fourth deadliest cancer in the U.S. and poised to move up within the next few years, pancreatic cancer is very difficult to detect in its early stages. Seldom diagnosed early and typically spreading rapidly, the disease has no effective treatment once it advances.

26 Aug 2015

Irreversible electroporation may prolong survival rates of patients with locally advanced pancreatic cancer

Use of irreversible electroporation (IRE) doubles the survival time for patients with locally advanced pancreatic cancer say researchers at the University of Louisville in a paper in the September edition of the Annals of Surgery.

25 Aug 2015

New set of genes can indicate improved survival after surgery for pancreatic cancer patients

A study by the Translational Genomics Research Institute and other major research institutes, found a new set of genes that can indicate improved survival after surgery for patients with pancreatic cancer. The study also showed that detection of circulating tumor DNA in the blood could provide an early indication of tumor recurrence.

21 Aug 2015

LINE-1 jumping gene unusually active in gastrointestinal cancer

Results of a trio of studies done on human cancer tissue biopsies have added to growing evidence that a so-called jumping gene called LINE-1 is active during the development of many gastrointestinal cancers.

19 Aug 2015

Studies show jumping genes more active during development of gastrointestinal cancers

18 Aug 2015

Tumor cells associated with pancreatic cancer work with each other to increase tumor spread

Tumor cells associated with pancreatic cancer often behave like communities by working with each other to increase tumor spread and growth to different organs. Groups of these cancer cells are better than single cancer cells in driving tumor spread, according to new research from the Perelman School of Medicine at the University of Pennsylvania published in Cancer Discovery online in advance of the print issue.

13 Aug 2015

UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

The University of New Mexico Cancer Center has been awarded the highest designation and rating in the United States for cancer treatment and research programs. It has received the National Cancer Institute's "NCI Comprehensive Cancer Center" designation, identifying it as one of the leading cancer centers in the nation and the only such cancer center in New Mexico.

13 Aug 2015

Scientists identify molecular partnership that may help explain how pancreatic cancer spreads

Scientists at the Johns Hopkins Kimmel Cancer Center have identified a molecular partnership in pancreatic cancer cells that might help to explain how the disease spreads — metastasizes — in some cases. Their findings reveal urgently needed new targets to treat pancreatic cancer, which strikes nearly 50,000 people in the U.S. each year and has only a 5 percent survival rate five years after diagnosis.

11 Aug 2015

VolitionRx reports net loss of $1.9 million for second quarter 2015

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the second quarter ended June 30, 2015.

11 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

High levels of specific proteins in urine can accurately detect early-stage pancreatic cancer

A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, UK researchers have found.

3 Aug 2015

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

The BRCA gene encodes for the BRCA proteins, BRCA1 and BRCA2. These proteins are very important in repairing DNA, which they do by correcting double-stranded breaks.

2 Aug 2015

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.

31 Jul 2015